In light of the fact that Erleada has just been approved for both HRMPC and Non-MPC, I think it would he helpful to all of us to understand what the differences and similarities are between these two drugs.
I just came off of the Titan Study for Erleada used for those of us with MPC, and so will be watching this with great interest. I was not eligible for the Erleada because I have already been switched over to Zytiga...but Erleada and Xtandi will be potential options for me in the future.
1. Will those who have taken Xtandi but have grown resistant- now get a benefit from Erleada in the future? Or vice versa?
2. Does one drug have less side effects or will they generally be the same?
3. What will the cost difference be?
4. There is a preferred order that these newer drugs and additional Chemo need to be taken in as one may reduce effectiveness of another. We need a flowchart showing the latest and most effective treatment plans for various stages each of us are in.
I am meeting with my oncologist again next week and will be asking her these questions.
But if others have had experience with or have researched these two drugs I would be curious to learn as much as we can.